Interferon Alfa News and Research

RSS
New combo drug helps suppress hepatitis C genotype 1 infection

New combo drug helps suppress hepatitis C genotype 1 infection

Boehringer Ingelheim announces new data from hepatitis C virus portfolio

Boehringer Ingelheim announces new data from hepatitis C virus portfolio

PROLOR receives U.S. patent allowance for CTP-modified interferons

PROLOR receives U.S. patent allowance for CTP-modified interferons

Innovative detection practices may prevent liver diseases

Innovative detection practices may prevent liver diseases

BMY announces PEG-Interferon lambda plus ribavirin Phase IIb trial results against HCV

BMY announces PEG-Interferon lambda plus ribavirin Phase IIb trial results against HCV

BMY announces BMS-790052 plus PEG-Interferon alfa and RBV Phase II trial results against HCV

BMY announces BMS-790052 plus PEG-Interferon alfa and RBV Phase II trial results against HCV

Experts must monitor new antiviral compounds for HCV treatment

Experts must monitor new antiviral compounds for HCV treatment

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting

Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting

FDA lifts clinical hold on Hemispherx's Alferon LDO Phase II study for influenza prevention

FDA lifts clinical hold on Hemispherx's Alferon LDO Phase II study for influenza prevention

Vertex announces modification of telaprevir and VX-222 combination Phase 2 trial for treatment of HCV

Vertex announces modification of telaprevir and VX-222 combination Phase 2 trial for treatment of HCV

Pharmasset initiates dosing in PSI-7977 exploratory study in HCV

Pharmasset initiates dosing in PSI-7977 exploratory study in HCV

Vertex submits NDA for telaprevir for treating hepatitis C

Vertex submits NDA for telaprevir for treating hepatitis C

Combining telaprevir regimen with standard therapy improves SVR rate in hepatitis C

Combining telaprevir regimen with standard therapy improves SVR rate in hepatitis C

Merck's boceprevir Phase III studies for HCV to be presented at 61st AASLD

Merck's boceprevir Phase III studies for HCV to be presented at 61st AASLD

Achillion initiates ACH-1625 Phase II dosing for HCV infection

Achillion initiates ACH-1625 Phase II dosing for HCV infection

Weight-based taribavirin reduces anemia, increases sustained virologic response

Weight-based taribavirin reduces anemia, increases sustained virologic response

Pharmasset commences dosing in PSI-7977 Phase 2b study for chronic hepatitis C

Pharmasset commences dosing in PSI-7977 Phase 2b study for chronic hepatitis C

LabCorp launches IL-28B gene test for HCV infection

LabCorp launches IL-28B gene test for HCV infection

Array BioPharma fiscal 2010 revenue increases to $53.9 million

Array BioPharma fiscal 2010 revenue increases to $53.9 million